We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Beta Blockers for Treatment of Pulmonary Arterial Hypertension in Children

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01723371
Recruitment Status : Withdrawn (Due to lack of enrollment.)
First Posted : November 7, 2012
Last Update Posted : December 31, 2015
Sponsor:
Information provided by (Responsible Party):
Mark Friedberg, The Hospital for Sick Children

Tracking Information
First Submitted Date  ICMJE October 31, 2012
First Posted Date  ICMJE November 7, 2012
Last Update Posted Date December 31, 2015
Study Start Date  ICMJE September 2012
Actual Primary Completion Date September 2015   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: November 5, 2012)
Incidence of Adverse Events [ Time Frame: Throughout study (Baseline to week 31) ]
-Incidence of major adverse effects defined as bradycardia, hypotension, and syncope, worsening of symptoms, disease state and death
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: November 5, 2012)
  • Improvement in the six minute walk test (6MWT) and cardiopulmonary exercise testing (CPX) [ Time Frame: Change over 6 months ]
    This will be measured by the difference in walking distance in the 6MWT and peak oxygen consumption in the CPX, between the baseline condition before the study and after 6 months with maintenance dose of carvedilol.
  • Improvement in echocardiogram and magnetic resonance imaging (MRI) parameters [ Time Frame: Change over 6 months ]
    The echocardiogram will be a subjective assessment of the right valve (RV) fractional area of change through TAPSE. The MRI will measure the RV ejection fraction. Both indicators will measure the different between the baseline condition before the study and after 6 months with maintenance dose of carvedilol.
  • Feasibility of carvedilol [ Time Frame: Baseline, Week 0, 2, 3, 4, 5, 6, 10, 18, 22, 30, 31 ]
    • Proportion of patients achieving target maintenance dose of carvedilol
    • Proportion of patients requiring dose adjustment due to bradycardia and/or hypertension
    • Proportion of patients stopping treatment with carvedilol due to serious adverse events
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Beta Blockers for Treatment of Pulmonary Arterial Hypertension in Children
Official Title  ICMJE Beta Blockers for Treatment of Pulmonary Arterial Hypertension in Children
Brief Summary This study will determine the safety and feasibility of using a β-blocker (in this case carvedilol) in the treatment of pediatric patients with Left Heart Failure (LHF) in children with Pulmonary Arterial Hypertension (PAH). Carvedilol affects the nervous system, the same system that is highly activated in response to stress in patients with PAH. Each patient is administered a dosage of carvedilol, according to their weight. This dosage is increased incrementally over the span of the study, if the patient responds well to the drug. The study will determine whether the potential adverse side effects of carvedilol outweigh the possible positive results in reducing LHF. The hypothesis of this study predicts that carvedilol will have positive effects in treating LHF, similar to their use in treatment of Right Heart Failure (RHF). This is a single-centered pilot study. Each patient will be studied for approximately 31 weeks.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Pulmonary Arterial Hypertension
Intervention  ICMJE Drug: Carvedilol
Carvedilol will be administered orally. The initial dose of carvedilol will be 0.05mg/kg/day divided into 2 doses. After two weeks, at subsequent weekly study visits, the dose of carvedilol will be increased incrementally to 0.1mg/kg in Week 2, 0.2mg/kg in Week 3, 0.4mg/kg in Week 4, 0.6mg/kg in Week 5, and 0.8mg/kg in Week 6, when the target dose of 0.8mg/kg/day (if weight is less than 62.5kg) or 50mg/day (if weight is greater than 62.5kg) is achieved. This dosage, assuming no adverse effects, will be maintained between Weeks 6 and 30 of the study. After the maintenance period from Week 6 to 30, patients will be weaned over 5 to 7 days or continued on a non-study drug supply.
Study Arms  ICMJE Experimental: Carvedilol
Intervention: Drug: Carvedilol
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Withdrawn
Actual Enrollment  ICMJE
 (submitted: December 30, 2015)
0
Original Estimated Enrollment  ICMJE
 (submitted: November 5, 2012)
10
Study Completion Date  ICMJE Not Provided
Actual Primary Completion Date September 2015   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Patients must be ≥ 8 and ≤ 17.5 years of age at the time of study enrollment.
  • Patients must have a mean pulmonary artery pressure of greater than 25mmHg at rest in a setting of normal pulmonary arterial wedge pressure of 15mmHg or less with a PVR index greater than 3 Woods units•m2 at last hemodynamic study.
  • Patients must be diagnosed with any of the following:Idiopathic PAH (IPAH), PAH associated with repaired congenital heart disease, PAH associated with minor congenital heart disease (small interventricular communication, small interarterial communication, small ductus arteriosis)
  • Patients must be clinically stable (i.e. no treatment changes) for the last 3 months
  • Patients must have no or minimal evidence of fluid overload or volume depletion judged by clinical evaluation (with or without diuretic treatment)
  • Written informed consent

Exclusion Criteria:

  • Patients who are unable to perform a six minute walk test (6MWT)
  • Patients with a known history of pulmonary hypertension secondary to venoocclusive disease and/or capillary hemangiomatosis; pulmonary hypertensions owing to left heart disease
  • Patients who have previously received treatment with an intravenous positive inotropic agent in the last 3 months
  • Patients who are currently receiving β-blockers
  • Patients with a known history of reactive airways disease (bronchial asthma or relate bronchospastic conditions)
  • Patients with chronic obstructive pulmonary disease (COPD)
  • Patients with a known history of adverse reaction to β-blockers
  • Patients with a heart block on ECG or resting heart rate < 60 bpm
  • Patients with systemic hypotension (below 5th percentile for age) are not eligible as follows: 1-10 years old: systolic blood pressure defined as < [70 + (2 x age in years)] mmHg; Older than 10 years: systolic blood pressure < 90 mmHg
  • Patients with coagulopathy (INR < 1.5 or platelet count <50,000/mm3)
  • Patients with a known history of severe hepatic impairment (defined by the presence of ascites, esophageal varices, jaundice or spider angiomata)
  • Patients with severe renal insufficiency (defined as creatinine clearance < 30 mL/min/m2)
  • Patients with a known malignancy or other co-morbidity expected to limit survival or to limit the ability to complete the study
  • Patients with trisomy 21
  • Patients with a known history of sick sinus syndrome
  • Patients with a known history of moderate or severe primary obstructive valvular heart disease
  • Patients with a known history of diabetes
  • Female patients who are pregnant of breast-feeding
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 8 Years to 17 Years   (Child)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Canada
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01723371
Other Study ID Numbers  ICMJE 1000031903
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Current Responsible Party Mark Friedberg, The Hospital for Sick Children
Original Responsible Party The Hospital for Sick Children
Current Study Sponsor  ICMJE The Hospital for Sick Children
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Mark Friedberg, MD The Hospital for Sick Children
PRS Account The Hospital for Sick Children
Verification Date December 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP